Article Information
- Received July 1, 2003
- Revision received August 5, 2003
- Accepted August 12, 2003
- First published November 26, 2003.
- Version of record published November 26, 2003.
Author Information
Author contributions
Disclosures
- Received July 1, 2003.
- Revision received August 5, 2003.
- Accepted August 12, 2003.
This research was supported by a National Alliance for Research on Schizophrenia and Depression-Pfizer Independent Investigator Award and National Institutes of Health Grant HL55312 to E.S.L. Technical expertise was provided by personnel of the Center for Genomic Sciences, a core facility of the Center for Human Genetics and Integrative Biology (University of Pittsburgh). Heteropodatoxin was kindly provided by NPS Pharmaceuticals. We thank Drs. R. H. Kramer, P. Shepard, and W. C. DeGroat for their comments.
Correspondence should be addressed to Edwin S. Levitan, Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA 15261. E-mail: Levitan{at}server.pharm.pitt.edu.
T.E. Tse's present address: Children's Hospital of Pittsburgh, Pittsburgh, PA 15213.
Copyright © 2003 Society for Neuroscience 0270-6474/03/2310859-08$15.00/0
